Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT06529016 · ClinicalTrials.gov registry record · NA
Using Dichoptic Therapy to Treat Intermittent Exotropia
A NA study of Exotropia Intermittent, sponsored by Virginia Commonwealth University.
- Recruiting
- Registry status
- NA
- Development phase
- 20
- Enrollment target
- 1
- Study location
NCT06529016: Recruiting NA study of Exotropia Intermittent, sponsored by Virginia Commonwealth University.
NCT06529016 is a NA study of Exotropia Intermittent that is actively recruiting participants, run by Virginia Commonwealth University. The registered enrollment target is 20 participants, below the 1,404-participant average among 58,714 other NA trials with a reported enrollment target (99% lower). The trial reports 1 study location across 1 state. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT06529016, a NA study of Exotropia Intermittent, is actively recruiting participants, sponsored by Virginia Commonwealth University.
- RECRUITING
- Registry status
- NA
- Development phase
- 20 participants
- Enrollment target
- 1
- Study location
Study Summary
Intermittent exotropia is difficult to treat. The mainstay of treatment involves surgery, and in one long-term study authors found that as many as 60% of IXT required at least one re-operation.Patching of the non-dominant eye has also been tested in a large, multi-center randomized control trial and was not found to have a large benefit. More non-surgical treatment modalities are critical to improve the care in this condition.
Primary Outcome
Improvement of the control of IXT using the Exotropia control scale that runs from 0-5. 0 meaning No exotropia noted unless dissociated, recovers in \< 1 seconds (exophoria). A 5 means Constant exotropia during 30-second observation before dissociation.
Conditions Studied
Interventions
- DEVICE Luminopia, a virtual reality headset
- OTHER Paper pre- survey
- OTHER Paper Survey
Study Locations (1)
Virginia
- Virginia Commonwealth University - Richmond
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 20 participants |
| Start Date | 2024-07-26 |
| Est. Completion | 2026-06 |
| Phase | NA |
What NCT06529016 shows while recruiting
NCT06529016 is an interventional study that assigns participants to a tested intervention. The registry caps enrollment at 20 participants, a relatively small participant target, below the 1,404-participant average among 58,714 other NA trials with a reported enrollment target (99% lower).
The record links to 1 condition, with Exotropia Intermittent appearing as the primary indexed condition, and to 3 interventions - of which Luminopia, a virtual reality headset is the first listed.
NCT06529016 reports a single indexed study location in Virginia.
Frequently Asked Questions
What is clinical trial NCT06529016 about?
NCT06529016 is a clinical study titled "Using Dichoptic Therapy to Treat Intermittent Exotropia". Intermittent exotropia is difficult to treat. The mainstay of treatment involves surgery, and in one long-term study authors found that as many as 60% of IXT required at least one re-operation.Patching of the non-dominant eye has also been tested in a large, multi-center randomized control trial and...
What is the current status of trial NCT06529016?
This trial is currently recruiting. It is a NA study. The enrollment target is 20 participants. The study started on 2024-07-26. Estimated completion is 2026-06.
What conditions does trial NCT06529016 study?
This clinical trial studies the following conditions: Exotropia Intermittent.
What interventions are being tested in trial NCT06529016?
The interventions under investigation include: Luminopia, a virtual reality headset (DEVICE), Paper pre- survey (OTHER), Paper Survey (OTHER).
Who is sponsoring clinical trial NCT06529016?
This trial is sponsored by Virginia Commonwealth University, which has 558 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT06529016 being conducted?
This trial has 1 study location across Virginia. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
How this trial's enrollment target compares
Where NCT06529016's enrollment target sits among peer trials
20 1769th of 2000 higher than 140 of 2,000 other NA trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other NA trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT00573339 · 20 participants
Cardiac Magnetic Resonance Imaging (MRI) Normal Reference Control Group Testing
- NCT00692939 · 20 participants · Phase 1
Autologous Stem Cell Transplantation for Crohn's Disease
- NCT00967785 · 20 participants · Phase 1
A Phase I Study of Mozobil in the Treatment of Patients With WHIMS
- NCT01406691 · 20 participants · Phase 4
Light Flashes to Treat Delayed Sleep Phase Disorder (DSPD)
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI